Affiliations
Kole R DeGolier, Etienne Danis, Marc D'Antonio, Jennifer Cimons, Michael Yarnell, Ross M Kedl, M Eric Kohler, James P Scott-Browne, Terry J Fry
DOI: 10.1038/s41590-024-02034-1
Abstract
Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational manipulations to control CAR T cell function. Here we examine the impact of cognate T cell antigen experience on subsequent CD8
Keywords
chimeric antigen receptor (CAR) T cells，CD15，CD8
